These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14751152)

  • 1. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
    Cloven NG; Kyshtoobayeva A; Burger RA; Yu IR; Fruehauf JP
    Gynecol Oncol; 2004 Jan; 92(1):160-6. PubMed ID: 14751152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
    Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB
    Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.
    Ikeda K; Sakai K; Yamamoto R; Hareyama H; Tsumura N; Watari H; Shimizu M; Minakami H; Sakuragi N
    Int J Gynecol Cancer; 2003; 13(6):776-84. PubMed ID: 14675314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.
    Nijman HW; Kenemans P; Poort-Keesom RJ; Verstraeten RA; Mensdorff-Pouilly S; Verheijen RH; Melief CJ; Hilgers J; Meijer CJ
    Eur J Obstet Gynecol Reprod Biol; 1999 Apr; 83(2):201-6. PubMed ID: 10391533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
    Tewari KS; Mehta RS; Burger RA; Yu IR; Kyshtoobayeva AS; Monk BJ; Manetta A; Berman ML; Disaia PJ; Fruehauf JP
    Gynecol Oncol; 2005 Sep; 98(3):360-8. PubMed ID: 16000215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
    Giurgea LN; Ungureanu C; Mihailovici MS
    Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic subtypes and laterality of primary epithelial ovarian tumors.
    Boger-Megiddo I; Weiss NS
    Gynecol Oncol; 2005 Apr; 97(1):80-3. PubMed ID: 15790441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.
    Malamou-Mitsi V; Crikoni O; Timotheadou E; Aravantinos G; Vrettou E; Agnantis N; Fountzilas G
    Anticancer Res; 2007; 27(2):1157-65. PubMed ID: 17465257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.